Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine.
In a single inpatient case study, a schizophrenic patient with tardive dyskinesia after prolonged treatment with typical neuroleptics was treated with the new atypical neuroleptic quetiapine, a dibenzothiazepin-derivative. Within 2 weeks of treatment with quetiapine, symptoms of tardive dyskinesia improved; 10 weeks after starting treatment tardive dyskinesia stopped completely. Over the same period, dopamine D2 receptor occupancy decreased substantially, as measured by IBZM-SPECT after 14 and 77 days of treatment.
Vesely
C
C
Department of General Psychiatry, University Hospital for Psychiatry, Vienna, Austria.
Küfferle
B
B
Brücke
T
T
Kasper
S
S
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D000069348:Quetiapine Fumarate; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D015899:Tomography, Emission-Computed, Single-Photon
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D017448:Receptors, Dopamine D2; D000069348:Quetiapine Fumarate